v3.26.1
Schedule of Segment Reporting Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Grant Revenue   $ 57,480   $ 336,108
Research and development            
Stock-based compensation     13,490   26,832  
Total research and development 131,130   880,835   464,464 1,282,987
General and administrative            
Depreciation         932 932
Stock-based compensation         611,995 637,170
Total general and administrative 807,548   977,373   1,722,117 1,951,790
Total Operating Loss (938,678)   (1,800,728)   (2,186,581) (2,898,669)
Other Income (Expense):            
Net Loss (988,716) $ (1,300,949) (1,852,081) $ (1,161,602) (2,289,665) (3,013,683)
Clinical Stage Biotechnology Segment [Member]            
Segment Reporting [Line Items]            
Grant Revenue   57,480   336,108
Research and development            
Conference and conventions 1,413     1,413
Clinical trial and research expenses 81,204   733,295   270,341 983,791
Insurance 40,304   51,827   79,967 99,816
Payroll and taxes (14,841)   73,773   63,177 155,952
Stock-based compensation 13,490   13,490   26,832 26,832
Rent and utilities 9,297   8,450   18,361 16,596
Travel and entertainment 263     4,373
Total research and development 131,130   880,835   464,464 1,282,987
General and administrative            
Depreciation 465   465   932 931
Directors’ fees 77,500   77,500   155,000 155,000
Donations     50,000
Insurance 33,173   26,194   68,477 52,954
Legal fees 79,446   125,133   222,797 246,155
Other general and administrative expenses 36,966   32,509   64,597 49,381
Payroll and taxes 137,144   224,404   358,817 441,117
Professional fees 139,323   178,303   249,278 336,930
Rent and utilities 5,381   4,333   10,675 8,984
Stock-based compensation 292,454   308,580   585,163 610,338
Travel and entertainment 5,696     6,381
Foreign currency transaction gains   (48)  
Total general and administrative 807,548   977,373   1,722,117 1,951,790
Total Operating Loss (938,678)   (1,800,728)   (2,186,581) (2,898,669)
Other Income (Expense):            
Research and development credit 281     281
Interest expense (50,319)   (51,353)   (103,365) (115,014)
Net Loss $ (988,716)   $ (1,852,081)   $ (2,289,665) $ (3,013,683)